Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

(2009) F. Castagnetti et al.   BLOOD

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

(2009) Michele Baccarani et al.   BLOOD

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

(2009) Yesid Alvarado et al.   CANCER

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

(2009) Hagop M. Kantarjian et al.   CANCER

High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

(2009) A Hochhaus et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

(2008) T. P. Hughes et al.   BLOOD

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

(2008) S. J. Lee et al.   BLOOD

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

(2008) C. S. Tam et al.   BLOOD

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

(2008) E. Jabbour et al.   BLOOD

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

(2008) A. Quintas-Cardama et al.   BLOOD

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

(2008) E. Jabbour et al.   BLOOD

The effects of imatinib on pregnancy outcome

(2008) S. M. Pye et al.   BLOOD

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

(2008) D. Marin et al.   BLOOD

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

(2008) W. Deenik et al.   BLOOD

Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment

(2008) T. Korff et al.   BLOOD

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

 4 1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells

(2008) J. Redondo-Munoz et al.   BLOOD

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

(2008) E. Jabbour et al.   BLOOD

15-deoxy- 12,14-PGJ2 enhances platelet production from megakaryocytes

(2008) J. J. O'Brien et al.   BLOOD

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD

Molecular monitoring in chronic myeloid leukemia

(2008) Elias Jabbour et al.   CANCER

No significance of derivative chromosome 9 deletion on the clearance kinetics ofBCR/ABLfusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia

(2008) Dong Hwan (Dennis) Kim et al.   CANCER

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy

(2008) Steven Richebourg et al.   CANCER GENETICS AND CYTOGENETICS

Nilotinib

(2008) M. W. Deininger   CLINICAL CANCER RESEARCH

Nilotinib

(2008) Greg L Plosker et al.   DRUGS

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome

(2008) F. Palandri et al.   HAEMATOLOGICA

Monitoring treatment of chronic myeloid leukemia

(2008) M. Baccarani et al.   HAEMATOLOGICA

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

(2008) T. Ernst et al.   HAEMATOLOGICA

Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression

(2008) Jamshid S. Khorashad et al.   JOURNAL OF CLINICAL ONCOLOGY

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

(2008) Dan Jones et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

(2008) A Shimoni et al.   LEUKEMIA

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

(2008) C M Lucas et al.   LEUKEMIA

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

(2008) A Hochhaus et al.   LEUKEMIA

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

(2007) Hagop Kantarjian et al.   CANCER